AC Immune (NASDAQ:ACIU) Given "Buy" Rating at HC Wainwright

AC Immune (NASDAQ:ACIU - Get Free Report)'s stock had its "buy" rating restated by analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They currently have a $16.00 price target on the stock. HC Wainwright's target price would indicate a potential upside of 401.57% from the stock's previous close.

Separately, StockNews.com downgraded AC Immune from a "buy" rating to a "hold" rating in a research report on Tuesday, October 1st.

AC Immune Trading Down 10.1 %

Shares of NASDAQ:ACIU traded down $0.36 during mid-day trading on Friday, reaching $3.19. The stock had a trading volume of 233,049 shares, compared to its average volume of 344,861. The company has a market cap of $315.62 million, a P/E ratio of -7.17 and a beta of 1.28. AC Immune has a 1 year low of $2.25 and a 1 year high of $5.14. The business's 50 day moving average price is $3.27 and its 200 day moving average price is $3.47.

Institutional Investors Weigh In On AC Immune

Several large investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. increased its stake in AC Immune by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company's stock worth $72,000 after acquiring an additional 7,400 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of AC Immune during the second quarter valued at approximately $218,000. Renaissance Technologies LLC grew its stake in shares of AC Immune by 26.4% during the second quarter. Renaissance Technologies LLC now owns 652,079 shares of the company's stock valued at $2,602,000 after buying an additional 136,300 shares during the last quarter. Vanguard Capital Wealth Advisors bought a new position in shares of AC Immune during the second quarter valued at approximately $56,000. Finally, Assenagon Asset Management S.A. grew its stake in shares of AC Immune by 294.7% during the second quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company's stock valued at $1,755,000 after buying an additional 328,312 shares during the last quarter. 51.36% of the stock is owned by institutional investors.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.